(Q37399899)

20 August 2017

1 reference

title

Beyond chemotherapy: targeted therapies in ovarian cancer (English)

1 reference

20 August 2017

1 reference

1 reference

Timothy A Yap

1

1 reference

20 August 2017

Craig P Carden

series ordinal

2

1 reference

20 August 2017

Stan B Kaye

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 March 2009

1 reference

20 August 2017

Nature Reviews Cancer

1 reference

20 August 2017

9

1 reference

20 August 2017

167-181

1 reference

20 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2583

20 August 2017

0 references

cites work

Global cancer statistics, 2002

1 reference

31 March 2020

Cancer statistics, 2008

1 reference

New therapies for ovarian cancer: cytotoxics and molecularly targeted agents

31 March 2020

1 reference

Ovarian cancer: strategies for overcoming resistance to chemotherapy

31 March 2020

1 reference

Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study

31 March 2020

1 reference

Surgical management of ovarian cancer

31 March 2020

1 reference

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

31 March 2020

1 reference

First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?

31 March 2020

1 reference

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

31 March 2020

1 reference

First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence

31 March 2020

1 reference

31 March 2020

Cancer statistics, 2001

1 reference

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

31 March 2020

1 reference

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study

31 March 2020

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

31 March 2020

1 reference

Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition

31 March 2020

1 reference

Angiogenesis in normal and neoplastic ovaries

31 March 2020

1 reference

Experience with bevacizumab in the management of epithelial ovarian cancer

31 March 2020

1 reference

The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model

31 March 2020

1 reference

Angiogenesis as a strategic target for ovarian cancer therapy

31 March 2020

1 reference

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

31 March 2020

1 reference

Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor

31 March 2020

1 reference

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

31 March 2020

1 reference

Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68).

31 March 2020

1 reference

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

31 March 2020

1 reference

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

31 March 2020

1 reference

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

31 March 2020

1 reference

Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?

31 March 2020

1 reference

Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize

31 March 2020

1 reference

Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model

31 March 2020

1 reference

The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis

31 March 2020

1 reference

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

31 March 2020

1 reference

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia

31 March 2020

1 reference

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

31 March 2020

1 reference

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study

31 March 2020

1 reference

Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer.

31 March 2020

1 reference

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).

31 March 2020

1 reference

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

31 March 2020

1 reference

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.

31 March 2020

1 reference

A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer

31 March 2020

1 reference

Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation

31 March 2020

1 reference

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

31 March 2020

1 reference

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

31 March 2020

1 reference

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

31 March 2020

1 reference

Studies with ZD1839 in preclinical models

31 March 2020

1 reference

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

31 March 2020

1 reference

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

31 March 2020

1 reference

Role of folate receptor genes in reproduction and related cancers

31 March 2020

1 reference

Folate receptor alpha as a tumor target in epithelial ovarian cancer

31 March 2020

1 reference

BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors

31 March 2020

1 reference

31 March 2020

1 reference

Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1.

31 March 2020

1 reference

Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer

31 March 2020

1 reference

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

31 March 2020

1 reference

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

31 March 2020

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

31 March 2020

1 reference

Hallmarks of 'BRCAness' in sporadic cancers

31 March 2020

1 reference

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

31 March 2020

1 reference

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

31 March 2020

1 reference

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

31 March 2020

1 reference

Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma

31 March 2020

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

31 March 2020

1 reference

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

31 March 2020

1 reference

Exploiting the PI3K/AKT pathway for cancer drug discovery

31 March 2020

1 reference

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

31 March 2020

1 reference

PIK3CA is implicated as an oncogene in ovarian cancer.

31 March 2020

1 reference

Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

31 March 2020

1 reference

Mutation of the PIK3CA gene in ovarian and breast cancer

31 March 2020

1 reference

PTEN and p53: who will get the upper hand?

31 March 2020

1 reference

PI3K/PTEN signaling in tumorigenesis and angiogenesis

31 March 2020

1 reference

The Akt/PKB pathway: molecular target for cancer drug discovery

31 March 2020

1 reference

Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway

31 March 2020

1 reference

Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer

31 March 2020

1 reference

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

31 March 2020

1 reference

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

31 March 2020

1 reference

Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms

31 March 2020

1 reference

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

31 March 2020

1 reference

Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers

31 March 2020

1 reference

An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

31 March 2020

1 reference

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

31 March 2020

1 reference

Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness

31 March 2020

1 reference

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

31 March 2020

1 reference

Translating basic cancer research into new cancer therapeutics

31 March 2020

1 reference

31 March 2020

1 reference

Initial sequencing and analysis of the human genome

31 March 2020

1 reference

The Sequence of the Human Genome

31 March 2020

1 reference

mTOR and cancer: reason for dancing at the crossroads?

31 March 2020

1 reference

Biomarkers in early clinical trials: the committed and the skeptics

31 March 2020

1 reference

Telomerase as a Target for Cancer Immunotherapy

31 March 2020

1 reference

How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development

31 March 2020

1 reference

Pharmacodynamic biomarkers for molecular cancer therapeutics

31 March 2020

1 reference

Effect of fixatives and tissue processing on the content and integrity of nucleic acids

31 March 2020

1 reference

Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases

31 March 2020

1 reference

31 March 2020

1 reference

An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites

31 March 2020

1 reference

Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer

31 March 2020

1 reference

Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer

31 March 2020

1 reference

Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells

31 March 2020

1 reference

Detection, clinical relevance and specific biological properties of disseminating tumour cells

31 March 2020

1 reference

Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis

31 March 2020

1 reference

Isolation of rare circulating tumour cells in cancer patients by microchip technology

31 March 2020

1 reference

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

31 March 2020

1 reference

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

31 March 2020

1 reference

A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer

31 March 2020

1 reference

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

31 March 2020

1 reference

A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer

31 March 2020

1 reference

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

31 March 2020

1 reference

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)

31 March 2020

1 reference

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

31 March 2020

1 reference

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.

31 March 2020

1 reference

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer

31 March 2020

1 reference

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study

31 March 2020

1 reference

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies

31 March 2020

1 reference

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

31 March 2020

1 reference

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer

31 March 2020

1 reference

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

31 March 2020

1 reference

12 December 2020

PPM1D is a potential therapeutic target in ovarian clear cell carcinomas

1 reference

12 December 2020

Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5

1 reference

12 December 2020

Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.

1 reference

12 December 2020

Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.

1 reference

12 December 2020

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1 reference

12 December 2020

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer

1 reference

12 December 2020

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

12 December 2020

Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells

1 reference

12 December 2020

Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity

1 reference

12 December 2020

EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients

1 reference

12 December 2020

A novel technique for the enrichment of primary ovarian cancer cells.

1 reference

12 December 2020

The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.

1 reference

12 December 2020

Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

1 reference

12 December 2020

Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy

1 reference

12 December 2020

Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases

1 reference

12 December 2020

Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash

1 reference

12 December 2020

Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model

1 reference

12 December 2020

Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis.

1 reference

12 December 2020

Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells

1 reference

12 December 2020

The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically

1 reference

12 December 2020

Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

1 reference

12 December 2020

Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha

1 reference

12 December 2020

Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms

1 reference

12 December 2020

Systemic treatment policies in ovarian cancer: the next 10 years

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC2583

1 reference

20 August 2017

1 reference